UFP Technologies Reports Strong Q3 2026 Growth Driven by MedTech Demand
UFP Technologies (UFPT) delivered a robust third quarter for 2026, reporting net sales of $172.4 million, an 11.6% increase year-over-year. The company's performance was bolstered by its MedTech segment, which saw 12.5% growth, and organic sales growth of 11.1%. Adjusted earnings per share rose to $2.88 from $2.39 in the prior year, reflecting improved operational efficiencies and higher volumes. Despite these gains, management noted headwinds including delays in transitioning AJR production activities to the Dominican Republic, which impacted potential cost savings. Additionally, the robotic surgery submarket remained flat to down for 2026. To drive future expansion, the company recently acquired CI Medical to enhance its injection molding and extrusion capabilities, aiming for a total growth framework of 12% to 18% through combined organic and inorganic initiatives.
Tickers: $UFPT
Topics: adjusted eps gross margin medtech segment net sales operating income